⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PRTA News
Prothena Corporation plc Ordinary Shares
PorTal Access, Inc. Announces Completion of FDA 510(k) Submission for Flexi-Port™, Marking Major Milestone Toward Commercial Launch
prnewswire.com
PRTA
Form 8-K
sec.gov
PRTA
Form 8-K
sec.gov
PRTA
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
businesswire.com
PRTA
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
businesswire.com
PRTA
Prothena Announces Leadership Team Updates
businesswire.com
PRTA
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
businesswire.com
PRTA
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
businesswire.com
PRTA
Form 8-K
sec.gov
PRTA
Prothena Announces up to $100 Million Share Repurchase Plan
businesswire.com
PRTA